Dr. Brandao meets Prof. Dr. Girard
In another intriguing discussion, Dr Brandao from the Institut Jules Bordet and Prof. Dr Nicolas Girard from the Institut Curie in Paris explored the implications of the latest data on patients with resectable non-small-cell lung cancer (NSCLC). The topic of their conversation revolved around the impact of recent studies presented at this year’s ASCO, such as CheckMate 816 and KeyNote 671, which have introduced new possibilities for patients. These studies build upon existing data from Neo Torch and Pacific-2. Prof. Girard aims to provide a comprehensive perspective on all these data.
In the second part of the interview, Dr Girard shares his experience with lurbinectedin, an alkylating agent utilized in France for the treatment of extensive-stage small-cell lung cancer. He delves into the details of its use and the outcomes observed in clinical practice.
With the educational support of:
